The complement system is a part of the immune system that can cause devastating diseases, and Achillion's focus is on developing orally administered factor D inhibitors to help patients with these conditions. In 2020, the company was acquired by Alexion Pharmaceuticals, and as part of Alexion, they continue to work towards their mission of transforming the lives of people with rare diseases.